Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Medicare & Medicaid Issues:

Medicare Advantage (Part C) and Prescription Drug (Part D) programs including quality measures and star ratings; third-party marketing tactics and broker compensation; prescription drug costs; risk adjustment; modernizing network composition and reforming benchmarks; advocated for differentiation in Medicare Part C and D reporting requirements; and transparency of Pharmacy Benefit Managers (PBMs).

Medicaid: Advocated on the implementation of the Medicaid provisions in the One Big Beautiful Bill Act; Advocated to ensure state Medicaid agencies use all forms of data available before requesting information from an enrollee.

Advocated in support of integration in Dual Eligible Special Needs Plans (D-SNPs) and advocated in support of redefinitions of HIDE-SNPs and FIDE-SNPs to ensure that states with behavioral health and LTSS carve-outs still qualify for the frailty adjustment.

Prescription Drug Pricing: Advocated on implementation of Part D provisions of the Inflation Reduction Act; advocated on drug pricing models being developed by the Center for Medicare & Medicaid Innovation drug pricing models; advocated for affordable cell and gene therapy drugs including the creation of a national risk-pool model; advocated for an end to patent thickets which are a barrier to lower cost biosimilars and generics entering the market; advocated for a ban on direct-to-consumer advertisements of drugs, including an end to the tax breaks that pharmaceutical manufacturers receive associated with direct-to-consumer ads; advocated for increased transparency requirements on pharmaceutical manufactures to list wholesale acquisition costs in drug ads and for expanded authorities for the Food and Drug Administration to better conduct oversight of direct-to-consumer advertisements.

Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instances of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans.

Telehealth: Advocated in support of permanent extension of telehealth flexibilities, in support of the CONNECT for Health Act and Telehealth Modernization Act; Advocated in support of an extension of the Acute Hospital Care at Home Program waivers; Advocated for legislation to repeal the requirement that doctors see Medicare beneficiaries in person within six months of being treated virtually for mental and behavioral health concerns (Telemental Health Care Access Act).

Provider Directories: Advocated on ensuring accuracy of provider directories including the creation of a national provider directory at CMS.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

General Health Care Issues:

Advocated on prescription drugs costs, including advocating for the transparency of PBMs and support for the Fair Accountability and Innovative Research (FAIR) Act; Advocated for patent reform and educated on the utilization of GLP-1s drugs; Advocated for the elimination of the separate interchangeability designation for biosimilars.

Mental and Behavioral Health: advocated in support of integration, collaborative care and access to mental and behavioral health services; advocated for greater access to mental and behavioral health services overall; advocated for greater access to tele-mental health services; advocated on mental health parity.

Prior Authorization: Advocated on regulation addressing electronic prior authorization to improve consumers access to appropriate care in a timely fashion, reduce instances of inappropriate or low-value care; Advocated on ensuring that health plans and providers share equally in the development and implementation of electronic prior authorization requirements. Advocated on prior authorization criteria requirements that are realistic for community-based health plans.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes